These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 689139)

  • 1. Diabetic microangiopathy in KK mice. IV. Effect of pyridinolcarbamate on kidney glucosyltransferase activity and glomerulosclerosis.
    Reddi AS; Oppermann W; Chen M; Camerini-Davalos RA
    Exp Mol Pathol; 1978 Oct; 29(2):149-55. PubMed ID: 689139
    [No Abstract]   [Full Text] [Related]  

  • 2. Diabetic microangiopathy in KK mice. II. Suppression of Glomerulosclerosis by pyridinolcarbamate.
    Reddi AS; Oppermann W; Velasco CA; Camerini-Davalos RA
    Exp Mol Pathol; 1977 Apr; 26(2):325-39. PubMed ID: 852540
    [No Abstract]   [Full Text] [Related]  

  • 3. Diabetic microangiopathy in KK mice. V. Effect of early glyburide treatment of kidney glucosyltransferase activity.
    Reddi AS; Oppermann W; Velasco C; Camerini-Davalos RA
    Exp Mol Pathol; 1978 Dec; 29(3):442-7. PubMed ID: 102528
    [No Abstract]   [Full Text] [Related]  

  • 4. Diabetic glomerulosclerosis in KK mice and its prevention by glyburide and pyridinolcarbamate.
    Camerini-Davalos RA; Reddi AS; Ehrenreich TH; Strugatz LH; Oppermann W
    Adv Exp Med Biol; 1979; 119():387-400. PubMed ID: 115232
    [No Abstract]   [Full Text] [Related]  

  • 5. Biopharmaceutical studies on pyridinolcarbamate. V. Effect of repeated administration of pyridinolcarbamate on the renal excretion of sulbenicillin in rabbits.
    Suenaga A; Nakagawa H; Huang MT; Imamura Y; Otagiri M; Ichibagase H
    Acta Pharm Suec; 1985; 22(1):45-52. PubMed ID: 4024967
    [No Abstract]   [Full Text] [Related]  

  • 6. Interaction between salicylic acid and repeatedly administered pyridinolcarbamate in rabbits.
    Suenaga A; Kinoshita Y; Imamura Y; Otagiri M; Ichibagase H
    Pharm Acta Helv; 1987; 62(8):221-5. PubMed ID: 3659058
    [No Abstract]   [Full Text] [Related]  

  • 7. Kidney disease in KK mice: structural, biochemical and functional relationships.
    Reddi AS; Wehner H; Khan MY; Camerini-Davalos RA
    Adv Exp Med Biol; 1988; 246():135-45. PubMed ID: 2854953
    [No Abstract]   [Full Text] [Related]  

  • 8. Modifications of platelet retention in patients treated with pyridinolcarbamate. A preliminary report.
    Girolami A; Peruffo R; Emanueli A
    Arzneimittelforschung; 1977; 27(6):1202. PubMed ID: 578441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pyridinolcarbamate (PDC) on surface microvessels in man: preliminary findings.
    Rouen LR; Terry EN; Clauss RH; Redisch W
    Bibl Anat; 1975; 13():358-9. PubMed ID: 1231780
    [No Abstract]   [Full Text] [Related]  

  • 10. [Rheographic normalization in prediabetic subjects treated with pyridinolcarbamate].
    Furitano G; Paterna S; Di Pasquale P
    Minerva Med; 1978 May; 69(24):1655-9. PubMed ID: 662168
    [No Abstract]   [Full Text] [Related]  

  • 11. Diabetic microangiopathy in KK mice. VI. Effect of glycemic control on renal glycoprotein metabolism and established glomerulosclerosis.
    Reddi AS; Velasco CA; Reddy PR; Khan MY; Camerini-Davalos RA
    Exp Mol Pathol; 1990 Oct; 53(2):140-51. PubMed ID: 2148155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of Prodectin on various blood clotting factors].
    Czaplicki S; Ostrowska B; Sułek K
    Pol Tyg Lek; 1978 Sep; 33(39):1541-4. PubMed ID: 704456
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of pyridinolcarbamate after acute and chronic administration in patients with atherosclerosis obliterans.
    Roztocil K; Oliva J; Linhart J; Prerovský I; Modr Z
    Int J Clin Pharmacol Biopharm; 1977 Mar; 15(3):135-8. PubMed ID: 844932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pyridinolcarbamate in diabetic angiopathies].
    Indovina I; Furitano G; Notarbartolo A; Citarrella P; Scaffidi A
    Minerva Med; 1978 May; 69(24):1681-97. PubMed ID: 566399
    [No Abstract]   [Full Text] [Related]  

  • 15. [Contribution of angioxine to the vascular protection of the diabetic].
    Journ Annu Diabetol Hotel Dieu; 1976 May; ():319-27. PubMed ID: 796526
    [No Abstract]   [Full Text] [Related]  

  • 16. [Experimental studies of parmidin (pyridinolcarbamate) effect on microvascular permeability of the lungs, skin and mesentery].
    Gorizontoba MP; Shvarts GIa
    Biull Eksp Biol Med; 1979 Sep; 88(9):272-5. PubMed ID: 519015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of repeated administration of pyridinolcarbamate on hypoglycemic activity after oral administration of acetohexamide in rabbits.
    Suenaga A
    Pharm Acta Helv; 1986; 61(4):125-8. PubMed ID: 3725809
    [No Abstract]   [Full Text] [Related]  

  • 18. [Inhibition of capillary permeability by a combination of pyridinolcarbamate and adenosine].
    Igual A; Vericat Cadesas F; Beaus R
    Arch Farmacol Toxicol; 1978 Apr; 4(1):88-9. PubMed ID: 697407
    [No Abstract]   [Full Text] [Related]  

  • 19. [Preliminary study of a work concerning the activity of pyridinol carbamate on diabetic angiopathy (study of the microcirculation)].
    Le Devehat C; Lemoine A
    Journ Annu Diabetol Hotel Dieu; 1977; ():389-93. PubMed ID: 894879
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of pyridinolcarbamate on lipid metabolism of normal and arteriosclerotic intima in human femoral arteries].
    Horsch AK; Gilli J; Schreiter U
    Verh Dtsch Ges Inn Med; 1974; 80():952-4. PubMed ID: 4454699
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.